OncoSec Medical Incorporated (NASDAQ: ONCS) made a new low in Friday’s trading session, to close the day with losses of 16.18%. Nonetheless, the company made some positive announcement on that day. The company released interim results for KEYNOTE-890, which is a continuing phase 2 study of TAVO together with KEYTRUDA, an anti-PD-1 checkpoint inhibitor in people suffering from Metastatic, chemotherapy-refractory triple negative breast cancer.

The company also announced that, patients who had recorded progress after 3 lines of chemotherapy were looped into KEYNOTE-890. The goal was to determine if the inclusion of TAVO could trigger significant clinical activity when in combination with KEYTRUDA.

The company provided the interim results at the San Antonio Breast Cancer Symposium. The results were made up of more than half of the 25 patients that took part in the KEYNOTE-890 to analyze for tumor responses, safety and immunology responses.

The company announced that, out of the 14 patients, 4 of them recorded a fast tumor reduction. They also recorded a partial response by RECIST v1.1 (ORR 28.5%) that also include deep partial response in a patient that had bone, skin, liver, and nodal metastases. It further announced that, all responses are in progress and that median DOR had not yet been attained. The company also announced that, the results compared favorably to the response rate noted in KEYTRUDA when used as a monotherapy.

A day earlier, the company sent a letter to shareholders explaining the importance of strategic transaction and partnership that it had with CGP and Sirtex. It noted that, the partnership gave it access to $30 million that will help unlock the value of TAVO. It also gives the company a chance to raise capital without putting more pressure on the stock price.

From the charts, the stock opened Friday’s session at $2.32 and traded between $1.95 and $2.43, before closing the day at $2.02. Volumes in the day stood at 338.7k.

About OncoSec Medical Incorporated

OncoSec Medical Incorporated is a biotech company that develops cytokine-based immunotherapies to stimulate the immune system to fight cancer. It is headquartered in Pennington, New Jersey.